Tagged: #immunotherapy

17
Jul
2019

Australia's Therapeutic Goods Administration (TGA) has today given Keytruda® (pembrolizumab) provisional approval for patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) bowel cancer.

Published in Latest News
29
Aug
2016
Researchers at the University of Otago are developing what may be a world-first vaccine for bowel cancer that works by fooling the immune system into believing tumours are invading viruses.
 
The University of Otago findings were presented at the 2016 International Congress of Immunology held in Melbourne this week.
Published in Latest News
Support Bowel Cancer Australia
Bowel Cancer Australia Social Media